2019年-2021年陕西省特药目录中抗肿瘤药可及性研究

Access to Anticancer Medicines in the Special Drug Catalogue of Shaanxi Province from 2019 to 2021

目的:探究陕西省特药目录中的抗肿瘤药品在定点医疗机构的可及性。方法:选取2019年—2021年陕西省特药目录中的31种抗肿瘤药品,利用药品的可获得性及药品利用情况等核心指标,评估抗肿瘤药品的可及性。结果:2019年—2021年,陕西省抗肿瘤药品在定点医疗机构的年均可获得性为1.4%—36.5%,西安市的年均可获得性(16.7%)显著高于省内其他地市,国谈药品的年均可获得性显著高于常规乙类药品,注射剂的年均可获得性显著高于口服常释制剂。陕西省31种抗肿瘤药品的总采购金额由2019年的2.63亿元上升至2021年的6.83亿元,西安地区总采购金额的年均增长率最高(70.3%),占陕西省年均总采购金额的64.0%。结论:陕西省特药目录中的抗肿瘤药品在定点医疗机构的可获得性、采购金额及用药频度均呈逐年上升趋势,整体可及性有待进一步提高。

Objective:We aim to investigate the accessibility of antitumor drugs in the special drug catalogue of Shaanxi Province in designated medical institutions.Methods:We selected 31 antitumor drugs in the special drug list of Shaanxi Province from 2019 to 2021,and evaluated the accessibility of antitumor drugs by core indicators such as availability and utilization of drugs.Results:From 2019 to 2021,the average annual availability of antitumor drugs in designated medical institutions was 1.4%to 36.5%.The highest availability occurred in Xi'an(16.7%),which was significantly higher than that of other regions in Shaanxi Province.The average annual availability of national negotiation drugs was significantly higher than that of conventional Class B drugs,and the average annual availability of injectable drugs was significantly higher than that of oral drugs.The total purchase amount of 31 antitumor drugs increased from 263 million Chinese yuan(CNY)in 2019 to CNY683 million in 2021.The highest average annual growth rate of procurement costs occurred in Xi'an(70.3%),accounting for 64.0%of total annual procurement in Shaanxi Province.Conclusions:The availability,purchase amount and DDDs of antitumor drugs in designate medical institutions in the special drug catalogue of Shaanxi Province increased annually,and the overall accessibility needs to be further improved.